Clinical expansion IntraOp's Mobetron UHDR system and focus on FLASH radiotherapy are driving clinical trial activity and presentations at ESTRO 2026, signaling growing adoption potential among cancer centers seeking advanced intraoperative electron therapy options.

Strategic partnerships With deployments at university hospitals and research centers worldwide, there is opportunity to partner with leading oncology centers and procurements teams that are already evaluating intraoperative electron therapy to broaden installed base and after-sales support networks.

Targeted markets The product’s portability and point-of-care delivery position IntraOp to pursue hospital systems and specialized cancer centers looking to enhance treatment accessibility and reduce patient wait times, particularly in multidisciplinary cancer programs.

Clinical trial funnel Active research initiatives, including Phase II Electron FLASH trials, indicate a pipeline of near-term clinical data that can be leveraged to expand use cases, justify budget approvals, and accelerate sales cycles within oncology departments.

Education and events Frequent participation in major industry events (AAPM, ESTRO, FRPT) provides opportunities to engage key decision-makers, deliver clinical evidence demonstrations, and drive value messaging around cost-effective, precise radiation therapy at the point of care.